Putnam Investments’s Cidara Therapeutics CDTX Stock Holding History

Putnam Investments’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,845	Closed	-$800K	–	1254
2016 Q4	$800K	Sell	3,845 -1,155	-23%	-$240K	﹤0.01%	1049
2016 Q3	$1.15M	Hold	5,000	–	–	﹤0.01%	993
2016 Q2	$1.03M	Hold	5,000	–	–	﹤0.01%	1097
2016 Q1	$1.27M	Hold	5,000	–	–	﹤0.01%	1055
2015 Q4	$1.72M	Hold	5,000	–	–	﹤0.01%	1016
2015 Q3	$1.27M	Hold	5,000	–	–	﹤0.01%	1112
2015 Q2	$1.4M	Buy	+5,000	New	+$1.54M	﹤0.01%	1149

Other funds holding CDTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Putnam Investments's CDTX Position: Q1 2017 in Review

Putnam Investments sold out of Cidara Therapeutics (CDTX) in Q1 2017, closing a stake of 3,845 shares — an estimated $800K sold.

Putnam Investments first reported a position in CDTX in Q2 2015 and held it in 7 quarters. The position peaked at $1.72M in Q4 2015. 54 funds tracked by Wall St. Rank hold CDTX as of Q1 2017.

Putnam Investments reported no remaining Cidara Therapeutics position as of Q1 2017 after selling out during the quarter.
Putnam Investments sold 3,845 Cidara Therapeutics shares in Q1 2017, an estimated $800K.
Putnam Investments first reported a position in Cidara Therapeutics in Q2 2015 and held it in 7 quarters.
Putnam Investments's Cidara Therapeutics position peaked at $1.72M in Q4 2015.
54 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2017.

Based on Putnam Investments's 13F filing for Q1 2017, filed 15 May 2017.